BrainsWay Ltd. American Depositary Shares (BWAY)
Fast GrowerFairStock Score: 45/100 — MIXED
Key Financials
| Current Price | $15.03 |
| Market Cap | $642M |
| P/E Ratio | 68.32 |
| ROE | 12.55% |
| Dividend Yield | —% |
| Sector | Healthcare |
Strengths
- Generates $814,250 in annual free cash flow (0.1% yield on market cap)
- Solid return on equity of 11.3% above cost of capital
- Conservative balance sheet with debt-to-equity of just 0.09, providing financial flexibility
- Altman Z-Score of 9.4 confirms minimal bankruptcy risk and strong solvency
- Revenue growth of 27.4% demonstrates strong top-line momentum
Concerns
- Trades significantly above Graham Number ($3) with negative 483% margin of safety—limited downside protection
AI Analysis
BrainsWay Ltd. American Depositary Shares is a micro-cap healthcare company valued at $642 million. The business generates $52 million in annual revenue with a 5.6% net margin and $814,250 in free cash flow. From a quality standpoint, BrainsWay shows Altman Z-Score of 9.4 confirms fortress-level solvency and adequate 11% ROE. On valuation, the stock is commanding a steep 87.5x multiple, with trades far above its Graham Number ($3) with no margin of safety. Growth dynamics show revenue growing at 27.4% and profit growth of 89.5%. Our composite FairStock Score of 45/100 reflects mixed fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.
Bull Case
BrainsWay's 27% revenue growth trajectory could accelerate as it captures additional market share in the healthcare sector. With $814,250 in annual free cash flow (0.1% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.
Bear Case
At 88x earnings, any growth disappointment triggers rapid multiple compression—a 20% earnings miss plus multiple contraction to 20x implies 40%+ downside. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.
Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer